{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:17:47Z","timestamp":1792034267934,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006390","name":"Universit\u00e9 de Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical hemolytic uremic syndrome (aHUS) is a rare disease in which uncontrolled terminal complement activation leads to systemic thrombotic microangiopathy (TMA). Pregnancy can trigger aHUS and, without complement inhibition, many women with pregnancy-triggered aHUS (p-aHUS) progress to end-stage renal disease (ESRD) with a high risk of morbidity. Owing to relatively small patient numbers, published characterizations of p-aHUS have been limited, thus the Global aHUS Registry (NCT01522183, April 2012) provides a unique opportunity to analyze data from a large single cohort of women with p-aHUS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The demographics and clinical characteristics of women with p-aHUS (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200951) were compared with those of women of childbearing age with aHUS and no identified trigger (non-p-aHUS,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009397). Outcome evaluations, including renal survival according to time to ESRD, were compared for patients with and without eculizumab treatment (a complement C5 inhibitor) in both aHUS groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline demographics and clinical characteristics were broadly similar in both groups. The proportion of women with p-aHUS and non-p-aHUS with pathogenic variant(s) in complement genes\u00a0and\/or anti-complement factor H antibodies was similar (45% and 43%, respectively), as was the proportion with a family history of aHUS (12% and 13%, respectively). Eculizumab treatment led to significantly improved renal outcomes in women with aHUS, regardless of whether aHUS was triggered by pregnancy or not: adjusted hazard ratio for time to ESRD was 0.06 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006) in the p-aHUS group and 0.20 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) in the non-p-aHUS group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Findings from this study support the characterization of p-aHUS as a complement-mediated TMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-021-01025-x","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T07:02:59Z","timestamp":1617778979000},"page":"1581-1590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis"],"prefix":"10.1093","volume":"34","author":[{"given":"Fadi","family":"Fakhouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Ardissino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Al-Dakkak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"7","key":"1025_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. NEJM 371(7):654\u2013666. https:\/\/doi.org\/10.1056\/NEJMra1312353","journal-title":"NEJM"},{"issue":"5","key":"1025_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.nefro.2015.07.005","volume":"35","author":"JM Campistol","year":"2015","unstructured":"Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Griny\u00f3 JM, Mac\u00eda M, Mendiz\u00e1bal S, Praga M, Rom\u00e1n E, Torra R, Vald\u00e9s F, Vilalta R, Rodr\u00edguez de C\u00f3rdoba S (2015) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 35(5):421\u2013447. https:\/\/doi.org\/10.1016\/j.nefro.2015.07.005","journal-title":"Nefrologia"},{"issue":"10095","key":"1025_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390(10095):681\u2013696. https:\/\/doi.org\/10.1016\/S0140-6736(17)30062-4","journal-title":"Lancet"},{"issue":"8","key":"1025_CR4","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/asn.2006080811","volume":"18","author":"AL Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18(8):2392\u20132400. https:\/\/doi.org\/10.1681\/asn.2006080811","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1025_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/cjn.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Desch\u00eanes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8(4):554\u2013562. https:\/\/doi.org\/10.2215\/cjn.04760512","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1025_CR6","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/cjn.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5(10):1844\u20131859. https:\/\/doi.org\/10.2215\/cjn.02210310","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1025_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","volume":"67","author":"CM Nester","year":"2015","unstructured":"Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ (2015) Atypical aHUS: state of the art. Mol Immunol 67(1):31\u201342. https:\/\/doi.org\/10.1016\/j.molimm.2015.03.246","journal-title":"Mol Immunol"},{"issue":"3","key":"1025_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fr\u00e9meaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodr\u00edguez de C\u00f3rdoba S, Roumenina LT, Sethi S, Smith RJ (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int 91(3):539\u2013551. https:\/\/doi.org\/10.1016\/j.kint.2016.10.005","journal-title":"Kidney Int"},{"issue":"4","key":"1025_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","volume":"14","author":"G Bayer","year":"2019","unstructured":"Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, M\u00e9rieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi J-M (2019) Etiology and outcomes of thrombotic microangiopathies. Clin J Am Soc Nephrol 14(4):557. https:\/\/doi.org\/10.2215\/CJN.11470918","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1025_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1681\/ASN.2009070706","volume":"21","author":"F Fakhouri","year":"2010","unstructured":"Fakhouri F, Roumenina L, Provot F, Sall\u00e9e M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey M-A, Bridoux F, Rondeau E, Fr\u00e9meaux-Bacchi V (2010) Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol JASN 21(5):859\u2013867. https:\/\/doi.org\/10.1681\/ASN.2009070706","journal-title":"J Am Soc Nephrol JASN"},{"issue":"8","key":"1025_CR11","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2215\/cjn.00280117","volume":"12","author":"A Bruel","year":"2017","unstructured":"Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Prov\u00f4t F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Fr\u00e9meaux-Bacchi V, Fakhouri F (2017) Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol 12(8):1237\u20131247. https:\/\/doi.org\/10.2215\/cjn.00280117","journal-title":"Clin J Am Soc Nephrol"},{"key":"1025_CR12","unstructured":"European Medicines Agency Ultomiris (ravulizumab). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ultomiris. Accessed Nov 2020"},{"key":"1025_CR13","unstructured":"European Medicines Agency Soliris (eculizumab). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf. Accessed Nov 2020"},{"key":"1025_CR14","unstructured":"US Food and Drug Administration Soliris (eculizumab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125166s431lbl.pdf. Accessed Nov 2020"},{"key":"1025_CR15","unstructured":"US Food and Drug Administration Ultomiris (ravuliazumab-cwvz). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761108s001lbl.pdf. Accessed Nov 2020"},{"issue":"23","key":"1025_CR16","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"},{"issue":"11","key":"1025_CR17","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","volume":"4","author":"E Rondeau","year":"2019","unstructured":"Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D (2019) Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry. Kidney Int Rep 4(11):1568\u20131576. https:\/\/doi.org\/10.1016\/j.ekir.2019.07.016","journal-title":"Kidney Int Rep"},{"issue":"3","key":"1025_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","volume":"4","author":"AM Siedlecki","year":"2018","unstructured":"Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ, Global aHUS Registry (2018) Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep 4(3):434\u2013446. https:\/\/doi.org\/10.1016\/j.ekir.2018.11.010","journal-title":"Kidney Int Rep"},{"issue":"12","key":"1025_CR19","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1681\/asn.2019040331","volume":"30","author":"J Zuber","year":"2019","unstructured":"Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Fr\u00e9meaux-Bacchi V (2019) Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol 30(12):2449\u20132463. https:\/\/doi.org\/10.1681\/asn.2019040331","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1025_CR20","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87(5):1061\u20131073. https:\/\/doi.org\/10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"issue":"3","key":"1025_CR21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NCAJ, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89(3):701\u2013711. https:\/\/doi.org\/10.1016\/j.kint.2015.11.026","journal-title":"Kidney Int"},{"issue":"1","key":"1025_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68(1):84\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.034","journal-title":"Am J Kidney Dis"},{"key":"1025_CR23","unstructured":"CinicalTrials.gov (2012) Atypical hemoloytic urermic syndrome (aHUS) registry (NCT01522183)"},{"key":"1025_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12882-015-0195-1","volume":"16","author":"C Licht","year":"2015","unstructured":"Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Fr\u00e9meaux-Bacchi V (2015) The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol 16:207\u2013207. https:\/\/doi.org\/10.1186\/s12882-015-0195-1","journal-title":"BMC Nephrol"},{"issue":"1","key":"1025_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/AOG.0000000000003554","volume":"135","author":"M Gupta","year":"2020","unstructured":"Gupta M, Govindappagari S, Burwick RM (2020) Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review. Obstet Gynecol 135(1):46\u201358","journal-title":"Obstet Gynecol"},{"issue":"2","key":"1025_CR26","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","volume":"94","author":"F Schaefer","year":"2018","unstructured":"Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommele A, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Fremeaux-Bacchi V (2018) Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 94(2):408\u2013418. https:\/\/doi.org\/10.1016\/j.kint.2018.02.029","journal-title":"Kidney Int"},{"issue":"12","key":"1025_CR27","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1681\/asn.2018070759","volume":"29","author":"F Bu","year":"2018","unstructured":"Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, Takanami E, Meyer NC, Frees K, Thomas CP, Nester C, Smith RJH (2018) Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol 29(12):2809\u20132819. https:\/\/doi.org\/10.1681\/asn.2018070759","journal-title":"J Am Soc Nephrol"},{"key":"1025_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2014.00097","author":"J Hofer","year":"2014","unstructured":"Hofer J, Rosales A, Fischer C, Giner T (2014) Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. https:\/\/doi.org\/10.3389\/fped.2014.00097","journal-title":"Front Pediatr"},{"issue":"2","key":"1025_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","volume":"93","author":"A Huerta","year":"2018","unstructured":"Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, Cavero T, Blasco M, Cao M, Manrique J, Cabello-Chavez V, Su\u00f1er M, Heras M, Fulladosa X, Belmar L, Sempere A, Peralta C, Castillo L, Arnau A, Praga M, Rodriguez de Cordoba S (2018) A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int 93(2):450\u2013459. https:\/\/doi.org\/10.1016\/j.kint.2017.06.022","journal-title":"Kidney Int"},{"issue":"1","key":"1025_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/1753495x17704563","volume":"11","author":"R Shanmugalingam","year":"2018","unstructured":"Shanmugalingam R, Hsu D, Makris A (2018) Pregnancy-induced atypical haemolytic uremic syndrome: a new era with eculizumab. Obstet Med 11(1):28\u201331. https:\/\/doi.org\/10.1177\/1753495x17704563","journal-title":"Obstet Med"},{"key":"1025_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.preghy.2018.02.007","volume":"12","author":"M Gupta","year":"2018","unstructured":"Gupta M, Feinberg BB, Burwick RM (2018) Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertens 12:29\u201334. https:\/\/doi.org\/10.1016\/j.preghy.2018.02.007","journal-title":"Pregnancy Hypertens"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-021-01025-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:56Z","timestamp":1777564496000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/5\/1581\/8325767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1007\/s40620-021-01025-x","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding update.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F Fakhouri has received fees for expertise, consultancy, and scientific symposia from Alexion Pharmaceuticals, Inc. M Scully has received speaker fees and is on an advisory board for Alexion Pharmaceuticals, Inc. G Ardissino has received speaker fees and is on an advisory board for Alexion Pharmaceuticals, Inc. I Al-Dakkak is an employee of, and may own stocks\/options in Alexion Pharmaceuticals, Inc. B Miller was an employee of Alexion Pharmaceuticals, Inc. at the time of this study. E Rondeau has received fees for expertise, consultancy, and scientific symposia from Alexion Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"A written informed consent was obtained from each patient prior to participation in the study. The Sponsor or its designee could provide an informed consent template to the sites, if required. If the site made any institution-specific modifications, the Sponsor or its designee could review the consent prior to IRB\/EC submission. The Investigator or the Sponsor would then submit the approved, revised consent to the appropriate IRB\/EC for review and approval prior to the start of the study. If the consent form was revised during the course of the study, all active participating patients to whom the revision may have had an impact must have signed the revised form. Before recruitment and enrollment, each patient was given a full explanation of the study and was allowed time to read the approved informed consent form. Once the Investigator was assured that the individual understood the implications of participating in the study, the patient was asked to give consent to participate in the study by signing the informed consent form. The Investigator provided a copy of the signed informed consent to the patient. The original form was maintained in the study files at the site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The sponsors of this study (Alexion Pharmaceuticals, Inc.) have provided consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This was a multicenter study comprising many different sites of enrollment. Federal, provincial, and local regulations and International Conference on Harmonization (ICH) guidelines, if relevant, required that approval was obtained from an Ethics Committee (EC)\/Independent review Board (IRB) prior to participation of patients in research studies. Where required and prior to the study onset, the EC\/IRB must have approved the protocol, Informed Consent, advertisements to be used for patient recruitment, and any other written information regarding this study to be provided to the patient or the patient\u2019s parents\/legal guardian. The sites maintained and made available for review by the Sponsor or its designee documentation of all EC\/IRB approvals and of the EC\/IRB compliance with ICH Guidance E6: Good Clinical Practice, if relevant. All EC\/IRB approvals were signed by the EC\/IRB Chairman or designee and identified the EC\/IRB name and address, the clinical protocol by title and\/or protocol number, and the date approval and\/or favorable opinion was granted. The Investigator conducted all aspects of this study in accordance with all national, provincial, and local laws of the pertinent regulatory authorities.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}